- Mantenha seus manipulados em locais secos, arejados e protegidos da luz
Prioritizing Health | Diabetes, Diet and GLP-1 RAs In 2021, the prevalence of type 2 diabetes (T2D) climbed to an estimated 38.4 million adults (nearly 15% of U.S
Geneva specializes in physician-supervised GLP-1 therapies (including semaglutide and tirzepatide), personalized nutrition planning, continuous follow up visits, and ongoing monitoring to ensure safe, steady, and sustainable results
Clinical Take-Home Messages GLP-1RAs are no longer diabetes-only drugs. They are becoming: Obesity therapies Cardiovascular protective agents Anti-inflammatory therapies Neuroprotective candidates Metabolic disease modifiers Conclusion We are witnessing a historic transition in medicine
The first-in-class, potent, and selective KRAS-G12D inhibitor, MRTX1133, has demonstrated significant tumor regression in both KRAS-G12D mutant cell line-derived and patient-derived xenograft models, which has led to the initiation of a Phase I/II clinical trial (NCT05737706) [105]
Applicable on select purchases across the Mamaearth, Dr